GlassScriptPhysician profile
Kazim Mohammed
NPI 1467911040
$7,762.43
in general payments reported to CMS, 2019-2025
23 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $999 · 2022: $1,490 · 2023: $1,631 · 2024: $2,102 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,273.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,269.96 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,079.24 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $818.82 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $528.71 | 2021-2024 | Uzedy, Austedo Xr, Austedo |
| Alkermes, INC. | $477.87 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $477.81 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $471.03 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $442.86 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $397.43 | 2021-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $290.91 | 2022-2025 | Auvelity |
| Lundbeck LLC | $251.61 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $224.85 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $216.49 | 2022-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $197.51 | 2023-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $143.06 | 2021-2025 | Loreev Xr, Sertraline Hcl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $140.38 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.71 | 2021-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $88.32 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $60.19 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.85 | 2024 | Abilify Maintena |
| Neos Therapeutics, LP | $16.39 | 2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $13.38 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazim Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.